iScience · 2026
Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Subramani Elavarasan, Pilié Patrick G, Slack-Tidwell Rebecca, Viscuse Paul V, Kuang Xianghong, Kandasamy Thirukumaran, Awad Dominik, Han Jenny J, Huang Licai, Peterson Christine B, Zurita Amado J, Subudhi Sumit K, Corn Paul G, Soundararajan Rama, Shepherd Peter, Piyarathna Badrajee, Putluri Vasanta, Putluri Nagireddy, Sreekumar Arun, Wang Yuzhuo, Zoubeidi Amina, Mahmud Iqbal, Martinez Sara A, Tan Lin, Lorenzi Philip L, Basu Sreyashi, Jindal Sonali, Sharma Padmanee, Logothetis Christopher J, Thompson Timothy C, Frigo Daniel E, Aparicio Ana M
Аннотация
Aggressive-variant prostate cancers (AVPCs) respond poorly to anti-androgen therapy but show sensitivity to taxane-platinum chemotherapy, though outcomes remain poor. We conducted a phase 2 trial testing induction cabazitaxel plus carboplatin (CabCarb) followed by olaparib maintenance versus observation in men with AVPC. The primary endpoint of improved progression-free survival (PFS) was not met, likely due to the study being underpowered after 38.5% of patients experienced early progression (ChemoPD) prior to randomization. No genomic alterations predicted ChemoPD; however, transcriptomic analysis revealed the enrichment of metabolic pathways, including arginine metabolism, in ChemoPD tumors. These findings were supported by metabolomics data from preclinical models. In AVPC models, arginine depletion with ADI-PEG20 enhanced CabCarb efficacy in vitro and in vivo. Together, these results provide insight into the heterogeneity of AVPCs and establish a rationale for novel combination treatment strategies to overcome chemotherapy resistance.